

Chapter 103

Pathophysiology and Clinical Aspects of Pruritus

Gil Yosipovitch & Tejesh S. Patel

REFERENCES

1. Yosipovitch G, Greaves M: Definitions of Itch. In: *Itch: Basic Mechanisms and Therapy*, edited by G Yosipovitch, MW Greaves, AB Fleischer Jr, F McGlone. New York, Marcel Dekker, 2004, pp. 1-4
2. Davidson S, Giesler GJ: The multiple pathways for itch and their interaction with pain. *Trends Neurosci* **33**(12):550-558, 2010
3. Yosipovitch G, Carstens E, McGlone F: Chronic itch and chronic pain: Analogous mechanisms. *Pain* **131**(1-2):4-7, 2007
4. Patel T, Yosipovitch G: Therapy of pruritus. *Expert Opin Pharmacother* **11**(10):1673-1682, 2010
5. Weisshaar E, Dalgard F: Epidemiology of itch: Adding to the burden of skin morbidity. *Acta Derm Venereol* **89**(4):339-350, 2009
6. Dalgard F et al: Self-reported skin morbidity in Oslo. Associations with sociodemographic factors among adults in a cross-sectional study. *Br J Dermatol* **151**(2):452-457, 2004
7. Yosipovitch G et al: Clinical characteristics of pruritus in chronic idiopathic urticaria. *Br J Dermatol* **147**(1):32-36, 2002
8. Van Loey NE et al: Itching following burns: Epidemiology and predictors. *Br J Dermatol* **158**(1):95-100, 2008
9. Lim YL et al: Pruritus is a common and significant symptom of acne. *J Eur Acad Dermatol Venereol* **22**(11):1332-1336, 2008
10. Reich A et al: Acne itch: Do acne patients suffer from itching? *Acta Derm Venereol* **88**(1):38-42, 2008
11. Razykov I et al: Prevalence and clinical correlates of pruritus in patients with systemic sclerosis. *Arthritis Rheum* **61**(12):1765-1770, 2009
12. Makunde WH et al: Clinical and parasitological aspects of itching caused by onchocerciasis in Morogoro, Tanzania. *Ann Trop Med Parasitol* **94**:793-799, 2000
13. Hicks MI, Elston DM: Scabies. *Dermatol Ther* **22**(4):279-292, 2009
14. Stander S et al: Clinical classification of itch: A position paper of the International Forum for the Study of Itch. *Acta Derm Venereol* **87**(4):291-294, 2007
15. Yosipovitch G et al: The brain processing of scratching. *J Invest Dermatol* **128**(7):1806-1811, 2008
16. Shelley WB, Arthur RP: The neurohistology and neurophysiology of the itch sensation in man. *AMA Arch Derm* **76**(3):296-323, 1957
17. Hilliges M, Wang L, Johansson O: Ultrastructural evidence for nerve fibers within all vital layers of the human epidermis. *J Invest Dermatol* **104**(1):134-137, 1995
18. Liu Q et al: Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus. *Cell* **139**(7):1353-1365, 2009
19. Yosipovitch G: The pruritus receptor unit: A target for novel therapies. *J Invest Dermatol* **127**(8):1857-1859, 2007
20. Inoue K et al: Functional vanilloid receptors in cultured normal human epidermal keratinocytes. *Biochem Biophys Res Commun* **291**(1):124-129, 2002
21. Schmelz M et al: Specific C-receptors for itch in human skin. *J Neurosci* **17**(20):8003-8008, 1997
22. Fruhstorfer H, Hermanns M, Latzke L: The effects of thermal stimulation on clinical and experimental itch. *Pain* **24**(2):259-269, 1986
23. Schmelz M et al: Active "itch fibers" in chronic pruritus. *Neurology* **61**(4):564-566, 2003
24. Schmelz M et al: Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. *J Neurophysiol* **89**(5):2441-2448, 2003
25. Andrew D, Craig AD: Spinothalamic lamina I neurons selectively sensitive to histamine: A central neural pathway for itch. *Nat Neurosci* **4**(1):72-77, 2001
26. Ikoma A et al: Painful stimuli evoke itch in patients with chronic pruritus: Central sensitization for itch. *Neurology* **62**(2):212-217, 2004

27. Ikoma A et al: Electrically evoked itch in humans. *Pain* **113**(1-2):148-154, 2005
28. Ishiiji Y et al: Repetitive scratching and noxious heat do not inhibit histamine-induced itch in atopic dermatitis. *Br J Dermatol* **158**(1):78-83, 2008
29. Davidson S et al: The itch-producing agents histamine and cowhage activate separate populations of primate spinothalamic tract neurons. *J Neurosci* **27**(37):10007-10014, 2007
30. Namer B et al: Separate peripheral pathways for pruritus in man. *J Neurophysiol* **100**(4):2062-2069, 2008
31. Reddy VB et al: Cowhage-evoked itch is mediated by a novel cysteine protease: A ligand of protease-activated receptors. *J Neurosci* **28**(17):4331-4335, 2008
32. Sun YG et al: Cellular basis of itch sensation. *Science* **325**(5947):1531-1534, 2009
33. Darsow U et al: New aspects of itch pathophysiology: Component analysis of atopic itch using the 'Eppendorf Itch Questionnaire'. *Int Arch Allergy Immunol* **124**(1-3):326-331, 2001
34. Yosipovitch G: Itch questionnaires as tools for itch evaluation. In: *Itch: Basic Mechanisms and Therapy*, edited by G Yosipovitch, MW Greaves, AB Fleischer Jr, F McGlone. New York, Marcel Dekker, 2004, p. 169
35. Yosipovitch G et al: Itch characteristics in Chinese patients with atopic dermatitis using a new questionnaire for the assessment of pruritus. *Int J Dermatol* **41**(4):212-216, 2002
36. Ishiiji Y et al: Distinct patterns of brain activity evoked by histamine-induced itch reveal an association with itch intensity and disease severity in atopic dermatitis. *Br J Dermatol* **161**(5):1072-1080, 2009
37. Mochizuki H et al: Time course of activity in itch-related brain regions: A combined MEG-fMRI study. *J Neurophysiol* **102**(5):2657-2666, 2009
38. Stander S et al: Neurophysiology of pruritus: Cutaneous elicitation of itch. *Arch Dermatol* **139**(11):1463-1470, 2003
39. Davies MG, Greaves MW: Sensory responses of human skin to synthetic histamine analogues and histamine. *Br J Clin Pharmacol* **9**(5):461-465, 1980
40. Greaves M, Shuster S: Responses of skin blood vessels to bradykinin, histamine and 5-hydroxytryptamine. *J Physiol* **193**(2):255-267, 1967
41. Sugimoto Y et al: Pruritus-associated response mediated by cutaneous histamine H3 receptors. *Clin Exp Allergy* **34**(3):456-459, 2004
42. Cowden JM, Zhang M, Dunford PJ, Thurmond RL: The histamine H(4) receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. *J Invest Dermatol* **130**(4):1023-1033, 2010
43. Rossbach K et al: Histamine H4 receptor antagonism reduces hapten-induced scratching behaviour but not inflammation. *Exp Dermatol* **18**(1):57-63, 2009
44. Steinhoff M et al: Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. *Nat Med* **6**(2):151-158, 2000
45. Luger TA: Neuromediators—A crucial component of the skin immune system. *J Dermatol Sci* **30**(2):87-93, 2002
46. Shimada SG, Shimada KA, Collins JG: Scratching behavior in mice induced by the proteinase-activated receptor-2 agonist, SLIGRL-NH2. *Eur J Pharmacol* **530**(3):281-283, 2006
47. Tsujii K et al: Activation of proteinase-activated receptors induces itch-associated response through histamine-dependent and -independent pathways in mice. *J Pharmacol Sci* **108**(3):385-388, 2008
48. Steinhoff M et al: Proteinase-activated receptor-2 mediates itch: A novel pathway for pruritus in human skin. *J Neurosci* **23**(15):6176-6180, 2003
49. Reddy VB, Shimada SG, Sikand P, Lamotte RH, Lerner EA: Cathepsin S elicits itch and signals via protease-activated receptors. *J Invest Dermatol* **130**(5):1468-1470, 2010
50. Grobe K et al: Properties of group I allergens from grass pollen and their relation to cathepsin B, a member of the C1 family of cysteine proteinases. *Eur J Biochem* **269**(8):2083-2092, 2002
51. Heyer G et al: Histamine-induced itch and alopecia (itchy skin) in atopic eczema patients and controls. *Acta Derm Venereol* **75**(5):348-352, 1995
52. Rukwied R, Heyer G: Cutaneous reactions and sensations after intracutaneous injection of vasoactive intestinal polypeptide and acetylcholine in atopic eczema patients and healthy controls. *Arch Dermatol Res* **290**(4):198-204, 1998
53. Wahlgren CF: Measurement of itch. *Semin Dermatol* **14**(4):277-284, 1995
54. Toyoda M et al: Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. *Br J Dermatol* **147**(1):71-79, 2002

55. Schmelz M et al: Mast cell tryptase in dermal neurogenic inflammation. *Clin Exp Allergy* **29**(5):695-702, 1999
56. Weidner C et al: Acute effects of substance P and calcitonin gene-related peptide in human skin—A microdialysis study. *J Invest Dermatol* **115**(6):1015-1020, 2000
57. Suzuki R et al: Direct neurite-mast cell communication in vitro occurs via the neuropeptide substance P. *J Immunol* **163**(5):2410-2415, 1999
58. Cocchiara R et al: Mast cell production of TNF-alpha induced by substance P evidence for a modulatory role of substance P-antagonists. *J Neuroimmunol* **101**(2):128-136, 1999
59. Imamachi N et al: TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms. *Proc Natl Acad Sci U S A* **106**(27):11330-11335, 2009
60. Shim WS et al: TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase. *J Neurosci* **27**(9):2331-2337, 2007
61. Yoshioka T et al: Impact of the Gly573Ser substitution in TRPV3 on the development of allergic and pruritic dermatitis in mice. *J Invest Dermatol* **129**(3):714-722, 2009
62. Sun YG, Chen ZF: A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. *Nature* **448**(7154):700-703, 2007
63. Fjellner B, Hagermark O: Potentiation of histamine-induced itch and flare responses in human skin by the enkephalin analogue FK-33-824, beta-endorphin and morphine. *Arch Dermatol Res* **274**(1-2):29-37, 1982
64. Bernstein JE, Swift R: Relief of intractable pruritus with naloxone. *Arch Dermatol* **115**(11):1366-1367, 1979
65. Fjellner B, Hagermark O: The influence of the opiate antagonist naloxone on experimental pruritus. *Acta Derm Venereol* **64**(1):73-75, 1984
66. Hagermark O: Peripheral and central mediators of itch. *Skin Pharmacol* **5**(1):1-8, 1992
67. Bergasa NV: An approach to the management of the pruritus of cholestasis. *Clin Liver Dis* **8**(1):55-66, vi, 2004
68. Togashi Y et al: Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. *Eur J Pharmacol* **435**(2-3):259-264, 2002
69. Umeuchi H et al: Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system. *Eur J Pharmacol* **477**(1):29-35, 2003
70. Yosipovitch G et al: Itch. *Lancet* **361**(9358):690-694, 2003
71. Pan ZZ: mu-Opposing actions of the kappa-opioid receptor. *Trends Pharmacol Sci* **19**(3):94-98, 1998
72. Bigliardi PL et al: Opioids and the skin—Where do we stand? *Exp Dermatol* **18**(5):424-430, 2009
73. Mendell LM, Albers KM, Davis BM: Neurotrophins, nociceptors, and pain. *Microsc Res Tech* **45**(4-5):252-261, 1999
74. Nakamura M, Toyoda M, Morohashi M: Pruritogenic mediators in psoriasis vulgaris: Comparative evaluation of itch-associated cutaneous factors. *Br J Dermatol* **149**(4):718-730, 2003
75. Raychaudhuri SP, Raychaudhuri SK: Role of NGF and neurogenic inflammation in the pathogenesis of psoriasis. *Prog Brain Res* **146**:433-437, 2004
76. Groneberg DA et al: Gene expression and regulation of nerve growth factor in atopic dermatitis mast cells and the human mast cell line-1. *J Neuroimmunol* **161**(1-2):87-92, 2005
77. Grewe M et al: Neurotrophin-4 production by human epidermal keratinocytes: Increased expression in atopic dermatitis. *J Invest Dermatol* **114**(6):1108-1112, 2000
78. Sonkoly E et al: IL-31: A new link between T cells and pruritus in atopic skin inflammation. *J Allergy Clin Immunol* **117**(2):411-417, 2006
79. Arita K et al: Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis. *Am J Hum Genet* **82**(1):73-80, 2008
80. Grimstad O et al: Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: A model of atopic dermatitis. *Exp Dermatol* **18**(1):35-43, 2009
81. Hagermark O, Strandberg K, Hamberg M: Potentiation of itch and flare responses in human skin by prostaglandins E2 and H2 and a prostaglandin endoperoxide analog. *J Invest Dermatol* **69**(6):527-530, 1977
82. Hagermark O, Strandberg K: Pruritogenic activity of prostaglandin E2. *Acta Derm Venereol* **57**(1):37-43, 1977
83. Greaves MW, McDonald-Gibson W: Itch: Role of prostaglandins. *Br Med J* **3**(5881):608-609, 1973

84. Daly BM, Shuster S: Effect of aspirin on pruritus. *Br Med J (Clin Res Ed)* **293**(6552):907, 1986
85. Yosipovitch G et al: The effect of topically applied aspirin on localized circumscribed neurodermatitis. *J Am Acad Dermatol* **45**(6):910-913, 2001
86. Arai I et al: Prostanoid DP1 receptor agonist inhibits the pruritic activity in NC/Nga mice with atopic dermatitis. *Eur J Pharmacol* **505**(1-3):229-235, 2004
87. Sugimoto M et al: Putative mechanism of the itch-scratch circle: Repeated scratching decreases the cutaneous level of prostaglandin D2, a mediator that inhibits itching. *Prostaglandins Leukot Essent Fatty Acids* **76**(2):93-101, 2007
88. Andoh T et al: Thromboxane A2 induces itch-associated responses through TP receptors in the skin in mice. *J Invest Dermatol* **127**(8):2042-2047, 2007
89. Dawn A et al: Itch characteristics in atopic dermatitis: Results of a web-based questionnaire. *Br J Dermatol* **160**(3):642-644, 2009
90. Yosipovitch G et al: The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. *Br J Dermatol* **143**(5):969-973, 2000
91. Pisoni RL et al: Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Nephrol Dial Transplant* **21**(12):3495-3505, 2006
92. Yosipovitch G, Papoiu AD: What causes itch in atopic dermatitis? *Curr Allergy Asthma Rep* **8**(4):306-311, 2008
93. Krause L, Shuster S: Mechanism of action of antipruritic drugs. *Br Med J (Clin Res Ed)* **287**(6400):1199-1200, 1983
94. Anderzen I et al: Stress and sensitization in children: A controlled prospective psychophysiological study of children exposed to international relocation. *J Psychosom Res* **43**(3):259-269, 1997
95. Arnetz BB et al: Endocrine and dermatological concomitants of mental stress. *Acta Derm Venereol Suppl (Stockh)* **156**:9-12, 1991
96. Ehlers A et al: Atopic dermatitis and stress: Possible role of negative communication with significant others. *Int J Behav Med* **1**(2):107-121, 1994
97. Arndt J, Smith N, Tausk F: Stress and atopic dermatitis. *Curr Allergy Asthma Rep* **8**(4):312-317, 2008
98. Bigliardi PL et al: Treatment of pruritus with topically applied opiate receptor antagonist. *J Am Acad Dermatol* **56**(6):979-988, 2007
99. Bigliardi-Qi M et al: Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitis. *Dermatology* **210**(2):91-99, 2005
100. Ersser SJ, Surrridge H, Wiles A: What criteria do patients use when judging the effectiveness of psoriasis management? *J Eval Clin Pract* **8**(4):367-376, 2002
101. Krueger G et al: The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. *Arch Dermatol* **137**(3):280-284, 2001
102. Sampogna F et al: Prevalence of symptoms experienced by patients with different clinical types of psoriasis. *Br J Dermatol* **151**(3):594-599, 2004
103. van de Kerkhof PC et al: Scalp psoriasis, clinical presentations and therapeutic management. *Dermatology* **197**(4):326-334, 1998
104. van de Kerkhof PC et al: Patient compliance and disease management in the treatment of psoriasis in the Netherlands. *Dermatology* **200**(4):292-298, 2000
105. Dawn A, Yosipovitch G: Treating itch in psoriasis. *Dermatol Nurs* **18**(3):227-233, 2006
106. Oaklander AL et al: Herpes zoster itch: Preliminary epidemiologic data. *J Pain* **4**(6):338-343, 2003
107. Wood GJ et al: An insatiable itch. *J Pain* **10**(8):792-797, 2009
108. Walcyk PJ, Elpern DJ: Brachioradial pruritus: A tropical dermatopathy. *Br J Dermatol* **115**(2):177-180, 1986
109. Wallengren J: Brachioradial pruritus: A recurrent solar dermatopathy. *J Am Acad Dermatol* **41**(4):657-658, 1999
110. Binder A et al: A case of neuropathic brachioradial pruritus caused by cervical disc herniation. *Nat Clin Pract Neurol* **4**(6):338-342, 2008
111. Lane JE, McKenzie JT, Spiegel J: Brachioradial pruritus: A case report and review of the literature. *Cutis* **81**(1):37-40, 2008
112. Eisenberg E, Barmeir E, Bergman R: Notalgia paresthetica associated with nerve root impingement. *J Am Acad Dermatol* **37**(6):998-1000, 1997
113. Yosipovitch G, Samuel LS: Neuropathic and psychogenic itch. *Dermatol Ther* **21**(1):32-41, 2008
114. Narita I et al: Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. *Kidney Int* **69**(9):1626-1632, 2006

115. Gilchrest BA et al: Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. *Ann Intern Med* **91**(1):17-21, 1979
116. Kuypers DR et al: A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. *Nephrol Dial Transplant* **19**(7):1895-1901, 2004
117. Silva SR et al: Thalidomide for the treatment of uremic pruritus: A crossover randomized double-blind trial. *Nephron* **67**(3):270-273, 1994
118. Patel TS, Freedman BI, Yosipovitch G: An update on pruritus associated with CKD. *Am J Kidney Dis* **50**(1):11-20, 2007
119. Kumagai H et al: Prospects for a novel μ -opioid receptor agonist, TRK-820, in uremic pruritus. In: *Itch: Basic Mechanisms and Therapy*, edited by G Yosipovitch, MW Greaves, AB Fleischer Jr, F McGlone. New York, Marcel Dekker, 2004, pp. 279-286
120. Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H: Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: A Phase III, randomized, double-blind, placebo-controlled study. *Nephrol Dial Transplant* **25**(4):1251-1257, 2010
121. Wikstrom B et al: Kappa-opioid system in uremic pruritus: Multicenter, randomized, double-blind, placebo-controlled clinical studies. *J Am Soc Nephrol* **16**(12):3742-3747, 2005
122. Carmichael AJ et al: Serological markers of renal itch in patients receiving long term haemodialysis. *Br Med J (Clin Res Ed)* **296**(6636):1575, 1988
123. Hampers CL et al: Disappearance of "uremic" itching after subtotal parathyroidectomy. *N Engl J Med* **279**(13):695-697, 1968
124. Wang H, Yosipovitch G: New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma. *Int J Dermatol* **49**:1-11, 2010
125. Ghent CN, Bloomer JR, Klatskin G: Elevations in skin tissue levels of bile acids in human cholestasis: Relation to serum levels and topuritus. *Gastroenterology* **73**(5):1125-1130, 1977
126. Thornton JR, Losowsky MS: Opioid peptides and primary biliary cirrhosis. *BMJ* **297**(6662):1501-1504, 1988
127. Bergasa NV et al: Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. *Ann Intern Med* **123**(3):161-167, 1995
128. Bergasa NV et al: Plasma from patients with the pruritus of cholestasis induces opioid receptor-mediated scratching in monkeys. *Life Sci* **53**(16):1253-1257, 1993
129. Bergasa NV et al: A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. *Gastroenterology* **102**(2):544-549, 1992
130. Bergasa NV et al: Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. *Am J Physiol* **268**(2 Pt 1):G346-G354, 1995
131. Bergasa NV et al: Cholestasis in the male rat is associated with naloxone-reversible antinociception. *J Hepatol* **20**(1):85-90, 1994
132. Oude Elferink RP et al: The molecular mechanism of cholestatic pruritus. *Dig Dis* **29**(1):66-71, 2011
133. Caravati CM Jr et al: Cutaneous manifestations of hyperthyroidism. *South Med J* **62**(9):1127-1130, 1969
134. Neilly JB et al: Pruritus in diabetes mellitus: Investigation of prevalence and correlation with diabetes control. *Diabetes Care* **9**(3):273-275, 1986
135. Scribner M: Diabetes and pruritus of the scalp. *JAMA* **237**(15):1559, 1977
136. Ross DR, Varipapa RJ: Treatment of painful diabetic neuropathy with topical capsaicin. *N Engl J Med* **321**(7):474-475, 1989
137. Yamaoka H et al: Truncal pruritus of unknown origin may be a symptom of diabetic polyneuropathy. *Diabetes Care* **33**(1):150-155, 2010
138. Gilbert HS, Warner RR, Wasserman LR: A study of histamine in myeloproliferative disease. *Blood* **28**(6):795-806, 1966
139. Archer CB, Camp RD, Greaves MW: Polycythaemia vera can present with aquagenic pruritus. *Lancet* **1**(8600):1451, 1988
140. Botero F: Pruritus as a manifestation of systemic disorders. *Cutis* **21**(6):873-880, 1978
141. Ishii T et al: Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. *Blood* **113**(23):5942-5950, 2009
142. Yosipovitch G: Chronic Pruritus: A Paraneoplastic Sign. *Dermatol Ther* **23**(6):590-596, 2010
143. Kantor GR, Lookingbill DP: Generalized pruritus and systemic disease. *J Am Acad Dermatol* **9**(3):375-382, 1983

144. Paul R, Paul R, Jansen CT: Itch and malignancy prognosis in generalized pruritus: A 6-year follow-up of 125 patients. *J Am Acad Dermatol* **16**(6):1179-1182, 1987
145. Duque MI, Yosipovitch G, Pegram S: Itch in HIV-infected patients. In: G Yosipovitch, M Greaves, AB Fleischer Jr, F McGlone. *Itch: Basic Mechanisms and Therapy*. New York, Marcel Dekker, 2004, p. 219
146. Mazeh D et al: Itching in the psychiatric ward. *Acta Derm Venereol* **88**(2):128-131, 2008
147. Kretzmer GE et al: Idiopathic pruritus in psychiatric inpatients: An explorative study. *Gen Hosp Psychiatry* **30**(4):344-348, 2008
148. Beaugregard S, Gilchrist BA: A survey of skin problems and skin care regimens in the elderly. *Arch Dermatol* **123**(12):1638-1643, 1987
149. Patel T, Yosipovitch G: The management of chronic pruritus in the elderly. *Skin Therapy Lett* **15**(8):5-9, 2010
150. Ward JR, Bernhard JD: Willan's itch and other causes of pruritus in the elderly. *Int J Dermatol* **44**(4):267-273, 2005
151. Ward RS et al: Substance P axons and sensory threshold increase in burn-graft human skin. *J Surg Res* **118**(2):154-160, 2004
152. Lee SS et al: Pruritus, pain, and small nerve fiber function in keloids: A controlled study. *J Am Acad Dermatol* **51**(6):1002-1006, 2004
153. Shelley WB, Rawnsley HM: Aquagenic urticaria. Contact sensitivity reaction to water. *JAMA* **189**:895-898, 1964
154. Greaves MW et al: Aquagenic pruritus. *Br Med J (Clin Res Ed)* **282**(6281):2008-2010, 1981
155. Gambichler T et al: A randomised controlled trial on photo(chemo)therapy of subacute prurigo. *Clin Exp Dermatol* **31**(3):348-353, 2006
156. McGrath JA, Greaves MW: Aquagenic pruritus and the myelodysplastic syndrome. *Br J Dermatol* **123**(3):414-415, 1990
157. Yosipovitch G, Fast K, Bernhard JD: Noxious heat and scratching decrease histamine-induced itch and skin blood flow. *J Invest Dermatol* **125**(6):1268-1272, 2005
158. Elias PM, Schmutz M: Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. *Curr Allergy Asthma Rep* **9**(4):265-272, 2009
159. Stander S et al: Treatment of pruritic diseases with topical calcineurin inhibitors. *Ther Clin Risk Manag* **2**(2):213-218, 2006
160. Senba E et al: The immunosuppressant FK506 activates capsaicin- and bradykinin-sensitive DRG neurons and cutaneous C-fibers. *Neurosci Res* **50**(3):257-262, 2004
161. Peier AM et al: A TRP channel that senses cold stimuli and menthol. *Cell* **108**(5):705-715, 2002
162. Patel T, Ishiuiji Y, Yosipovitch G: Menthol: A refreshing look at this ancient compound. *J Am Acad Dermatol* **57**(5):873-878, 2007
163. Yosipovitch G et al: Effect of topically applied menthol on thermal, pain and itch sensations and biophysical properties of the skin. *Arch Dermatol Res* **288**(5-6):245-248, 1996
164. Papoiu AD, Yosipovitch G: Topical capsaicin. The fire of a "hot" medicine is reignited. *Expert Opin Pharmacother* **11**(8):1359-1371, 2010
165. Weisshaar E et al: Effect of topical capsaicin on the cutaneous reactions and itching to histamine in atopic eczema compared to healthy skin. *Arch Dermatol Res* **290**(6):306-311, 1998
166. Young TA et al: A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. *J Dermatol Treat* **20**(2):76-81, 2009
167. Yosipovitch G, Maibach HI: Effect of topical pramoxine on experimentally induced pruritus in humans. *J Am Acad Dermatol* **37**(2 Pt 1):278-280, 1997
168. Freitag G, Hoppner T: Results of a postmarketing drug monitoring survey with a polidocanol-urea preparation for dry, itching skin. *Curr Med Res Opin* **13**(9):529-537, 1997
169. Drake LA, Fallon JD, Sober A: Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. The Doxepin Study Group. *J Am Acad Dermatol* **31**(4):613-616, 1994
170. Szepietowski JC, Reich A, Szepietowski T: Emollients with endocannabinoids in the treatment of uremic pruritus: Discussion of the therapeutic options. *Ther Apher Dial* **9**(3):277-279, 2005
171. Peer G et al: Randomised crossover trial of naltrexone in uraemic pruritus. *Lancet* **348**(9041):1552-1554, 1996
172. Wolfhagen FH et al: Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study. *Gastroenterology* **113**(4):1264-1269, 1997
173. Terg R et al: Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. *J Hepatol* **37**(6):717-722, 2002

174. Metzke D et al: Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. *J Am Acad Dermatol* **41**(4):533-539, 1999
175. Bailey AG et al: Epidural morphine combined with epidural or intravenous butorphanol for post-operative analgesia in pediatric patients. *Anesth Analg* **79**(2):340-344, 1994
176. Gunter JB et al: Continuous epidural butorphanol relieves pruritus associated with epidural morphine infusions in children. *Paediatr Anaesth* **10**(2):167-172, 2000
177. Dawn AG, Yosipovitch G: Butorphanol for treatment of intractable pruritus. *J Am Acad Dermatol* **54**(3):527-531, 2006
178. Davis MP et al: Mirtazapine for pruritus. *J Pain Symptom Manage* **25**(3):288-291, 2003
179. Hundley JL, Yosipovitch G: Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: A pilot study. *J Am Acad Dermatol* **50**(6):889-891, 2004
180. Stander S et al: Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: Results of an open-labelled, two-arm proof-of-concept study. *Acta Derm Venereol* **89**(1):45-51, 2009
181. Ehrchen J, Stander S: Pregabalin in the treatment of chronic pruritus. *J Am Acad Dermatol* **58**(2 Suppl.):S36-S37, 2008
182. Duval A, Dubertret L: Aprepitant as an antipruritic agent? *N Engl J Med* **361**(14):1415-1416, 2009
183. Nilsson HJ, Levinsson A, Schouenborg J: Cutaneous field stimulation (CFS): a new powerful method to combat itch. *Pain* **71**(1):49-55, 1997
184. Wallengren J, Sundler F: Cutaneous field stimulation in the treatment of severe itch. *Arch Dermatol* **137**(10):1323-1325, 2001
185. Pfab F, Huss-Marp J, Gatti A et al: Influence of acupuncture on type I hypersensitivity itch and the wheal and flare response in adults with atopic eczema—a blinded, randomized, placebo-controlled, crossover trial. *Allergy* **65**(7):903-910, 2010
186. Pfab F et al: Preventive effect of acupuncture on histamine-induced itch: A blinded, randomized, placebo-controlled, crossover trial. *J Allergy Clin Immunol* **116**(6):1386-1388, 2005
187. Yamamoto Y et al: Association between frequency of pruritic symptoms and perceived psychological stress: A Japanese population-based study. *Arch Dermatol* **145**(12):1384-1388, 2009
188. Gieler U et al: Psychosomatic aspects of pruritus. In: *Itch: Basic Mechanisms and Therapy*, edited by G Yosipovitch, MW Greaves, AB Fleischer Jr, F McGlone. New York, Marcel Dekker, 2004, p. 343
189. Tran BW, Papoiu AD, Russoniello CV, Wang H, Patel TS, Chan YH, Yosipovitch G: The Effect of itch, scratching and mental stress on autonomic nervous system in atopic eczema. *Acta Derm Venereol* **90**(4):354-361, 2010
190. van Os-Medendorp H et al: Effectiveness of the nursing programme 'Coping with itch': A randomized controlled study in adults with chronic pruritic skin disease. *Br J Dermatol* **156**(6):1235-1244, 2007

